Operator: Tycho Peterson, JPMorgan.

Evan Lodes - JPMorgan: This is Evan Lodes for Tycho. I guess first question was for Gary. Can you disaggregate the slowdown in benign dVH between the seasonal effects that you mentioned such as deductibles and then also the more coordinated efforts that you talked about with regards to the rollout specifically?

Gary S. Guthart, Ph.D. - President and CEO: I think I heard the question, although there's a little bit of background noise on the call. I think the question was can we disaggregate the benign hysterectomy slowdown. I think there are few things going on there. As we look at multi-port benign hysterectomy in total, we think our market opportunity is really the open surgical market share. There's still more than 100,000 open benign hysterectomies being done in the U.S. We see three issues impacting benign hysterectomy. First, as we become a larger part of the market, the impact of seasonality plays proportionately bigger role in our performance. Said, simply one of the new technique is a small part of the market, the number of un-served patients is sufficiently large that changes in the total number of patient admissions do not materially impact growth. However, as penetration increases, the sensitivity of the total admission increases with it. Second, several large healthcare organizations are reporting a greater than expected decline in patient admissions in the first quarter. Given that, benign hysterectomy is a large part of our procedure based – that will impact us as well. Third, negative press has some hard to measure impact on benign hysterectomy, although doesn't appear to be large, it's also probably not zero.

Evan Lodes - JPMorgan: Then as a second question, you mentioned the international procedure growth was about 14%. Could you help us think about what the growth is in Europe and trends there that you've seen recently?

Calvin Darling - Senior Director of Finance: Just numerically, the 14% would be higher on the Asia and Rest of World markets and a bit lower on the European side.

Operator: Benjamin Andrew, William Blair.

Benjamin Andrew - William Blair: Gary, talk a little bit about the guidance of 20% to 23%, and targeting kind of the low-end of that range. What does it take for you to hit that 20%, does it require a stabilization in benign dVH and again continues that stabilization of prostatectomy, and just maybe walk through how you get to that 20%, because we're struggling a little bit as we try to plug in the number for Q1 to get there?

Gary S. Guthart, Ph.D. - President and CEO: A couple of things and then, Calvin may help you a little bit with that as well. But as we look out, we've seen three quarter in a row with prostatectomy where it's sort of finding its footing with regard to U.S. We're assuming that the remains – that trend stays about the same as we go through. General surgery has shown real strength. On benign gynecology, I want to make sure we're separating out gynecologic procedures from just hysterectomy. There is more in benign gynecology to just hysterectomy, there is myomectomy, cyclocryopexy, both of which were meeting our expectations in this quarter. Quarter's a little bit hard to interpret just because of the number of operating days and there's little bit of ambiguity as to how many there were in terms of how the (holidays) played. And we'll have to see a little bit, impossible to predict the future perfectly we look out and think that our guidance at the low end makes sense giving those kind of three factors together.